The company also announces that the new WFI grade water product will be available through the online catalog in November.
HOLLISTER, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development and commercialization of drug therapies, novel vaccines and molecular diagnostics, announced the creation of a early access for two new products currently in development to streamline the development of the downstream gene therapy process, including an anion exchange buffer (AEX) screening kit and a functional reporter assay. The company also announced the upcoming launch of a new WFI Quality Water product, which will be available through the company’s online catalog offering in November.
Speaking at the Cell & Gene annual meeting on the Mesa, Stephen Gunstream, President and CEO of Teknova, noted that the company’s research and development team is focused on developing new products and services. to address critical issues in the development of gene therapies.
“We are leveraging our expertise in end-to-end gene therapy workflows to develop new personalized product innovations aimed at solving key bioprocessing bottlenecks,” said Gunstream. “Our initial products aim to streamline the development of AAV therapies by providing our customers with the tools to quickly optimize their process, enabling high recovery and purity of their AAV product.”
The first product, an Anion Exchange Buffer (AEX) Screening Kit, is designed to allow AAV gene therapy developers to quickly identify the optimal buffer formulation for capsid enrichment based on their specific serotype, transgene and AEX platform. The second is a functional reporter assay using RNA detection technology intended to measure viral functional performance as a function of the gene of interest.
Teknova is still in the early stages of developing the AEX Buffer Screening Kit and Functional Reporter Assay. To accelerate and promote the development of both products, they seek to partner with companies entering or currently working in the downstream AAV purification process. To learn more about Teknova’s Early Access Program, visit www.teknova.com.
The company also announced that in response to customer interest, it will begin manufacturing WFI grade water, which will be available through its online product catalog in 20L and 200L bags, from from November 2022. The company will provide more details at launch. the dates are approaching.
Teknova accelerates clinical breakthroughs in the life sciences by providing customized products and reagents for drug therapies, novel vaccines and molecular diagnostics. With a focus on agility and customization, Teknova offers research- and GMP-grade products, including cell culture media and supplements, protein and nucleic acid purification buffers, and biology reagents. molecule for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics and synthetic biology. Teknova’s proprietary processes enable the manufacture and delivery of high-quality, custom-designed, bespoke products with short turnaround times and at scale through all stages of development, including commercialization.
Investor Contacts Matt Lowell Chief Financial Officer email@example.com +1 831-637-1100 Sara Michelmore MacDougall Advisors firstname.lastname@example.org +1 781-235-3060 Media Contact Jenn Henry Senior Vice President, Marketing email@example.com +1 831-313-1259